Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use.
about
The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitisBesifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial InfectionsIntegrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes.Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics.Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis.Besifloxacin ophthalmic suspension: emerging evidence of its therapeutic value in bacterial conjunctivitis.The role of besifloxacin in the treatment of bacterial conjunctivitis.Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis.Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.Development and Validation of Different Ultraviolet-Spectrophotometric Methods for the Estimation of Besifloxacin in Different Simulated Body Fluids.Anti-inflammatory effects of besifloxacin, a novel fluoroquinolone, in primary human corneal epithelial cells.
P2860
Q24631812-29DFED07-E4F1-46E8-8785-567265D71270Q26752242-324EC0CF-AEB5-4B1F-B464-70E83546192CQ35410079-11A52077-E3DA-4F43-B308-0C005EB35955Q37367643-581E6497-A777-4D88-B01D-2E2CD2F3E0C6Q37594797-587CD866-C71E-49E7-82EC-E7CC7A7118F4Q38021408-DE7D5A74-440B-4E6F-B47B-E02E4BFDC11DQ38122147-11C5739F-BA53-4887-9DD7-D147124190D7Q38190827-43E9BE59-EFAD-48C6-B80B-7EB047A22A15Q40273599-D415FB72-AE7C-4B0B-B059-4BD6D571D270Q40953254-2AC8DF63-FF39-44BD-8463-55DC807E4C09Q41915114-6387B416-D8F5-465E-B9E0-CCB4522C62FBQ46196742-E37B4963-DB3F-4F42-815A-DA97308BF0C2
P2860
Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Nonclinical pharmacodynamics, ...... nt for topical ophthalmic use.
@ast
Nonclinical pharmacodynamics, ...... nt for topical ophthalmic use.
@en
Nonclinical pharmacodynamics, ...... nt for topical ophthalmic use.
@nl
type
label
Nonclinical pharmacodynamics, ...... nt for topical ophthalmic use.
@ast
Nonclinical pharmacodynamics, ...... nt for topical ophthalmic use.
@en
Nonclinical pharmacodynamics, ...... nt for topical ophthalmic use.
@nl
prefLabel
Nonclinical pharmacodynamics, ...... nt for topical ophthalmic use.
@ast
Nonclinical pharmacodynamics, ...... nt for topical ophthalmic use.
@en
Nonclinical pharmacodynamics, ...... nt for topical ophthalmic use.
@nl
P2093
P356
P1476
Nonclinical pharmacodynamics, ...... nt for topical ophthalmic use.
@en
P2093
Jean-François Lepage
Jean-Yves Driot
Keith W Ward
P304
P356
10.1089/JOP.2006.0137
P577
2007-06-01T00:00:00Z